Publish in this journal
Journal Information
Vol. 46. Issue 9.
Pages 508-520 (September 2022)
Download PDF
More article options
Vol. 46. Issue 9.
Pages 508-520 (September 2022)
Update in Intensive Care Medicine: Severe infections due to multi-resistant gram-negative bacilli
Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections
Tratamiento de las infecciones graves por Pseudomonas aeruginosa multirresistente
E. Díaz Santosa,b, C. Mora Jiméneza, L. del Río-Carbajoc, P. Vidal-Cortésc,
Corresponding author

Corresponding author.
a Medicina Intensiva, Consorci Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
b Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain
c Medicina Intensiva, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
Article information
Full Text
Download PDF
Figures (2)
Tables (1)
Table 1. Activity of new antibiotics against the different resistance mechanisms of PA.

Pseudomonas aeruginosa is the microorganism most frequently involved in the main ICU-acquired infections, with special importance in ventilator associated pneumonia. Its importance lies, in addition to its high incidence in critically ill patients, in the severity of the infections it causes and in the difficulty of its antimicrobial treatment, directly related to the high percentage of resistance to antibiotics classically considered first-line. New active antibiotics have recently been developed against Pseudomonas aeruginosa, even against multi-drug resistant strains. This review analyzes both the differential characteristics of Pseudomonas aeruginosa infections and the new therapeutic options, focusing on multi-drug resistant Pseudomonas aeruginosa.

Pseudomonas aeruginosa
Gramnegative bacillus
Multidrug-resistant bacteria
Ventilator-associated pneumonia

Pseudomonas aeruginosa es el microorganismo que participa con mayor frecuencia en las principales infecciones adquiridas en la UCI, con especial importancia en la neumonía asociada a ventilación mecánica. Su importancia radica, además de en su elevada incidencia en el paciente crítico, en la gravedad de las infecciones que causa y en la dificultad de su tratamiento antimicrobiano, directamente relacionada con el elevado porcentaje de resistencias a los antibióticos considerados clásicamente de primera línea. Recientemente se han desarrollado nuevos antibióticos activos frente a Pseudomonas aeruginosa, incluso frente a cepas multirresistentes. La presente revisión analiza tanto las características diferenciales de las infecciones por Pseudomonas aeruginosa como las nuevas opciones terapéuticas, centrando el foco en la Pseudomonas aeruginosa multirresistente.

Palabras clave:
Pseudomonas aeruginosa
Bacilo gramnegativo
Bacterias multirresistentes
Neumonía asociada a la ventilación


These are the options to access the full texts of the publication Medicina Intensiva (English Edition)
If you are a member of the Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias::
Go to the members area of the website of the SEMICYUC ( )and click the link to the magazine.

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Intensiva (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Medicina Intensiva (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?